A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Study Identifier
M25-207
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Toxins
  • Study Drug
  • AGN-151586
  • OnabotulinumtoxinA
  • Placebo
  • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+ years

    Protocol Summary

    The objective of this Phase 1 study is to assess the safety and efficacy of single treatment of AGN-151586 and of OnabotulinumtoxinA in the glabellar complex of participants with moderate to severe glabellar lines (GL).

    Study Locations

    Location
    Status
    Location
    Investigate MD /ID# 270771
    Scottsdale, Arizona, United States, 85260
    Status
    Not applicable
    Location
    Eye Research Foundation /ID# 270827
    Newport Beach, California, United States, 92663
    Status
    Not applicable
    Location
    Marcus Facial Plastic Surgery /ID# 270770
    Redondo Beach, California, United States, 90277
    Status
    Not applicable
    Location
    Skin Research Institute LLC /ID# 270831
    Coral Gables, Florida, United States, 33146-1837
    Status
    Not applicable
    Location
    Skincare Physicians /ID# 271018
    Chestnut Hill, Massachusetts, United States, 02467
    Status
    Not applicable
    Location
    Wilmington Dermatology Center /ID# 270828
    Wilmington, North Carolina, United States, 28403
    Status
    Not applicable
    Showing {first} - {last} of {total} Results